Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
March 28, 2024 08:05 ET
|
Tevogen Bio Inc
The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
Tevogen Bio Announces Series A-1 Preferred Stock Investment
March 27, 2024 09:20 ET
|
Tevogen Bio Inc
The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress
March 20, 2024 02:00 ET
|
BioSenic
PRESS RELEASE Preclinical data in a transgenic mouse model shows beneficial effects on various clinical symptoms analogous to those observed in human systemic sclerosis.Findings may further support...
CAR-T Cell Therapies Market with a Target Valuation of USD 7.9 billion by 2032 | Dynamic CAGR of 13.8%
January 17, 2024 08:12 ET
|
Market.Us
New York, Jan. 17, 2024 (GLOBE NEWSWIRE) -- According to Market.us, the CAR-T cell Therapies market size is projected to surpass around USD 7.9 billion by 2032, from USD 2.5 Billion, and is poised...
Life Science Tools Market Size Anticipated to Hit USD 367.16 Billion by 2032
January 09, 2024 11:25 ET
|
Precedence Research
Ottawa, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The global life science tools market size stood at USD 122.58 billion in 2023, and grew to USD 136.17 billion in 2024, as a result of the growing R&D...
Global Neuromodulation Market Size & Share to Surpass $14.8 Billion by 2030 | Vantage Market Research
November 22, 2023 11:15 ET
|
Vantage Market Research
WASHINGTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- According to Vantage Market Research, the Global Neuromodulation Market is estimated to be valued at USD 14.8 Billion by 2030 at an exponential growth...
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
November 03, 2023 14:00 ET
|
ImCheck Therapeutics SAS
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 Interim data from EVICTION-2 study confirms safety and tolerability...
VEON’s Jazz and Turkcell Announce BIP Partnership
December 15, 2022 06:00 ET
|
VEON Ltd.
VEON’s Jazz enables 194 Million Mobile Users in Pakistan to Get Access to BiP App’s Media, Messaging and Instant Translations over 100 Languages Amsterdam, 15 December 2022: VEON Ltd....
Hyris' New T-Cell Test is Finally Available to EU Countries to Easily Map Patients' Cellular Immunity to SARS-CoV-2
August 05, 2022 08:00 ET
|
Hyris
LONDON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- As the pandemic crisis has entered a new phase, it is a common belief among the scientific community that COVID-19 is here to stay, maybe for a long time....
Single Cell Bioinformatics Software and Services Global Market Outlook to 2031: Rapid Development in the Single Cell Technologies and Advancing Field of Disease Diagnosis and Drug Discovery
June 27, 2022 04:08 ET
|
Research and Markets
Dublin, June 27, 2022 (GLOBE NEWSWIRE) -- The "Single Cell Bioinformatics Software and Services Market - A Global and Regional Analysis: Focus on Product, Application, End-User, and Region -...